Physician profile
Daniel M Ryan
NPI 1730195231
$1,059.93
in general payments reported to CMS, 2019-2025
18 companies · $27.16 in 2025
The $27.16 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $187 · 2021: $163 · 2022: $165 · 2023: $161 · 2024: $57.17 · 2025: $27.16.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.31 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $345.60 | 2019-2023 | Ztlido |
| Allergan, INC. | $162.99 | 2019-2021 | |
| Abbvie INC. | $131.04 | 2021-2024 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $86.67 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $64.86 | 2023 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $37.09 | 2021-2023 | Belbuca |
| Amgen INC. | $35.23 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $27.16 | 2025 | |
| Pfizer INC. | $25.92 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.11 | 2022 | |
| Hikma Pharmaceuticals USA | $21.00 | 2023 | Kloxxado |
| Ani Pharmaceuticals, INC. | $20.50 | 2024 | Purified Cortrophin Gel |
| Orthogenrx INC. | $17.54 | 2019 | |
| Mdd US Operations, LLC | $13.38 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.33 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $13.21 | 2022 | |
| Horizon Therapeutics Plc | $12.06 | 2022 | |
| Kaleo, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.